Trulieve Cannabis (OTCMKTS:TCNNF) Upgraded to “Buy” at Compass Point

Compass Point upgraded shares of Trulieve Cannabis (OTCMKTS:TCNNF) from a neutral rating to a buy rating in a research note published on Monday, Benzinga reports. Compass Point currently has $17.00 price objective on the stock, up from their prior price objective of $11.00.

TCNNF opened at $13.13 on Monday. The stock has a fifty day moving average price of $10.87 and a 200 day moving average price of $10.18. Trulieve Cannabis has a 1 year low of $6.68 and a 1 year high of $16.23.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge.

Recommended Story: Backdoor Roth IRA

Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with's FREE daily email newsletter.